NewLimit

South San Francisco, United States

NewLimit is a biotech company developing epigenetic therapies to extend human healthspan by reprogramming aging cells.

$435.0M raised

Jun 2026

Series C

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has NewLimit raised?

NewLimit has raised $435.0M in total funding. The most recent round was Series C. The last funding was announced in June 2026.

Who are NewLimit's investors?

NewLimit's investors include Draper Associates, Founders Fund, Khosla Ventures, Thrive Capital, Kleiner Perkins.

Where is NewLimit headquartered?

NewLimit is headquartered in South San Francisco, United States.

What does NewLimit do?

NewLimit is a biotech company developing epigenetic therapies to extend human healthspan by reprogramming aging cells.

What stage is NewLimit at?

NewLimit is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 2, 2026.

MLA

"NewLimit — Funding & Investors." VCBacked, June 2, 2026, https://www.vcbacked.co/company/newlimit. Accessed July 2, 2026.

APA

VCBacked. (2026). NewLimit — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/newlimit

Wikipedia (cite web)

{{cite web |title=NewLimit — Funding & Investors |url=https://www.vcbacked.co/company/newlimit |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 2, 2026.